ANNUAL REPORT 2012 - TiGenix

More documents

Recommendations

Info

Title Country Application number Use of CXCL6 chemokine in the prevention or repair of cartilage defects (PCT Publication WO2005/014026) (Continued) Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production. (PCT Publication WO2008/061804) Biopsy Device (PCT Publication WO/2010/092100) B. TiGenix Trademark Portfolio JP NO NZ RU SG JP522,851/2006 NO20060464 NZ545,702 RU2006107536 SG18893 US US 10/595,072 US-CIP1 US EP AU CA CN HK IN IL JP NZ NO RU SG US12/345,369 US12/515488 EP07846847 AU2007324705 CA2670419 CN200780043440 HK1136964 2830/DELNP/2009 IL198794 JP2009-537561 NZ576330 NO20091571 RU2009123960 SG200903163 AU 2010212842 CA CN CA2752797 CN201080012848.6 EA 201101177 EP 10707483.3 IL 214630 IN JP IN6375/DELNP/2011 JP549550/11 US 13/201686 The table below provides an overview of TiGenix’s registered trademark and registration pending trademark applications. Registered trademarks are highlighted in white. Country Trademark Classes Europe (CTM) CELLERIX 5, 10 & 42 Spain RETROFECT 35 Europe (CTM) IDRYON 10 Europe (CTM) ONTARIL 5 Europe (CTM) MIREDAL 5 Europe (CTM) LIVING MEDICINES 16 & 35 Europe (CTM) CELLERIX LIVING MEDICINES 5, 10 & 42 Europe (CTM) ALOCELLIX 3 & 5 Europe (CTM) ADICELL-X 3 & 5 Europe (CTM) CELLERIX (Graphic) 5, 10 & 42 Europe (CTM) ALOFISEL 3 & 5 208 TiGenix I annual report 2012
Country Trademark Classes USA CELLERIX (Graphic) 5 & 42 USA ONTARIL 5 USA CELLERIX LIVING MEDICINES 5 & 42 Austria 5, 10 & 42 Benelux 5, 10 & 42 Canada 5, 10 & 42 Denmark 5, 10 & 42 Finland 5, 10 & 42 France 5, 10 & 42 ChondroCelect Germany 5, 10 & 42 Italy 5, 10 & 42 Norway 5, 10 & 42 Spain 5, 10 & 42 Sweden 5, 10 & 42 Switzerland 5, 10 & 42 United Kingdom 5, 10 & 42 United States 5, 10 & 42 Austria 5 & 42 Benelux 5, 10, 41 & 42 Canada 5 & 42 Croatia 5 & 42 Denmark 5 & 42 Finland 5 & 42 France 5 & 42 TiGenix Germany 5 & 42 Italy 5 & 42 Norway 5 & 42 Spain 5 & 42 Sweden 5 & 42 Switzerland 5 & 42 United Kingdom 5 & 42 United States 1 & 5 ChondroBoost Benelux 5, 10 & 42 CCI Benelux 5, 10 & 42 US 1, 5, 10, 42 & 45 MeniscoCelect Europe (CTM) 5, 10 & 42 US 1, 5, 10, 42 & 45 Benelux 5, 10 & 44 CCH US 10, 44 & 42 Canada 5, 10 & 42 Europe (CTM) 5, 10 & 42 209
Page 1 and 2:
ANNUAL REPORT 2012
Page 3 and 4:
9. MAJOR SHAREHOLDERS 103 9.1. OVER
Page 5 and 6:
There can be no assurance that TiGe
Page 7 and 8:
educing their ultimate value to the
Page 9 and 10:
eimbursement in certain instances s
Page 11 and 12:
or the relevant manufacturing proce
Page 13 and 14:
In recent years, it expanded its op
Page 15 and 16:
making this change may be costly an
Page 17 and 18:
TiGenix’s development stage produ
Page 19 and 20:
qualified employees and consultants
Page 21 and 22:
1. Introduction Annual report 2012
Page 23 and 24:
2. Persons Responsible for the Cont
Page 25 and 26:
4. Selected Financial Information Y
Page 27 and 28:
5.3. ORGANISATIONAL STRUCTURE TiGen
Page 29 and 30:
Date Transaction Number and class o
Page 31 and 32:
Date Transaction Number and class o
Page 33 and 34:
(12) The shares were subscribed to
Page 35 and 36:
5.5. DESCRIPTION OF RIGHTS AND BENE
Page 37 and 38:
Formalities to attend the sharehold
Page 39 and 40:
amendments to the Articles of Assoc
Page 41 and 42:
the existing shareholders have a pr
Page 43 and 44:
Issue date Term Number of warrants
Page 45 and 46:
6. Business Overview Most of the in
Page 47 and 48:
6.2. COMPETITIVE STRENGTHS The Comp
Page 49 and 50:
6.3. IMPORTANT EVENTS IN THE DEVELO
Page 51 and 52:
6.3.5. Funding history Since its in
Page 53 and 54:
non-weight bearing area of the join
Page 55 and 56:
6.4.5. Commercial launch ChondroCel
Page 57 and 58:
und Behandlungsmethode”) in sever
Page 59 and 60:
Therapeutics (product Hyalograft C)
Page 61 and 62:
Different routes of administration
Page 63 and 64:
Clinical development In January 201
Page 65 and 66:
evenues from this pipeline within t
Page 67 and 68:
that the average cost of treatment
Page 69 and 70:
TiGenix has obtained cGMP status fo
Page 71 and 72:
Biologics for treatment of Rheumato
Page 73 and 74:
of the patents and patent applicati
Page 75 and 76:
- “Marker genes for use in the id
Page 77 and 78:
manufacturing process and therapeut
Page 79 and 80:
Invalidation of US patent US6777231
Page 81 and 82:
7. Corporate Governance 7.1. GENERA
Page 83 and 84:
7.2.3. Independent directors As to
Page 85 and 86:
7.2.4. Composition of the Board of
Page 87 and 88:
of Ravago NV, Vanbreda Risk & Benef
Page 89 and 90:
Litigation statement concerning the
Page 91 and 92:
As proof of the independence and an
Page 93 and 94:
for their healthcare and biotechnol
Page 95 and 96:
7.5. SCIENTIFIC ADVISORY BOARD AND
Page 97 and 98:
As of the date of publication of th
Page 99 and 100:
(rounded down to the nearest intege
Page 101 and 102:
usiness at customary market conditi
Page 103 and 104:
9. Major Shareholders 9.1. OVERVIEW
Page 105 and 106:
10. Financial Statements : General
Page 107 and 108:
11. Consolidated Financial Statemen
Page 109 and 110:
11.3. CONSOLIDATED STATEMENT OF CAS
Page 111 and 112:
The consolidated financial statemen
Page 113 and 114:
11.5.2.2. Basis of consolidation Th
Page 115 and 116:
are provided and costs are incurred
Page 117 and 118:
of interest on the remaining balanc
Page 119 and 120:
Deferred tax assets and liabilities
Page 121 and 122:
- Partnering of Cx601 (i.e. finding
Page 123 and 124:
The Group is mainly exposed to the
Page 125 and 126:
fiscal year 2010, reference is made
Page 127 and 128:
Sales and marketing expenses Years
Page 129 and 130:
The number of employees in the R&D
Page 131 and 132:
Analysis of profit/(loss) for the p
Page 133 and 134:
(8) Disposal group held for sale Th
Page 135 and 136:
(10) Property, plant and equipment
Page 137 and 138:
The decrease of stock in 2012 compa
Page 139 and 140:
dividends will be based upon the Co
Page 141 and 142:
alance. As a consequence, the Compa
Page 143 and 144:
(23) Other current liabilities The
Page 145 and 146:
TiGenix SAU - Stock options Prior t
Page 147 and 148:
(25) Business combination Descripti
Page 149 and 150:
(26) Related party transactions Tra
Page 151 and 152:
(28) Commitments and contingencies
Page 153 and 154:
(30) Consolidation scope Name Subsi
Page 155 and 156:
We believe that the audit evidence
Page 157 and 158: assets and liabilities, its financi
Page 159 and 160: the results of its operations and c
Page 161 and 162: 12.2. STATUTORY BALANCE SHEET 2010-
Page 163 and 164: The value of receivables is reduced
Page 165 and 166: 13. Annual Report of the Board of D
Page 167 and 168: 2013. The facility will provide the
Page 169 and 170: year ended December 31, 2011, and T
Page 171 and 172: Operating result (EBIT) and net res
Page 173 and 174: Statement of financial position The
Page 175 and 176: - The total personnel costs of EUR
Page 177 and 178: - TiGenix may fail in successfully
Page 179 and 180: continue as a going concern and to
Page 181 and 182: Functioning of the Board of Directo
Page 183 and 184: The nomination and remuneration com
Page 185 and 186: Apart from the above remuneration f
Page 187 and 188: Shares and warrants held by indepen
Page 189 and 190: - Long-term incentive plan : warran
Page 191 and 192: Shares and warrants held by executi
Page 193 and 194: - identifying and implementing busi
Page 195 and 196: actual bonus equal to 78 % of her p
Page 197 and 198: was reduced to a half-time role com
Page 199 and 200: 14. Business and Financial Update a
Page 201 and 202: Financial results for the full year
Page 203 and 204: 15. Available Documents The Company
Page 205 and 206: Title Country Application number Ce
Page 207: Title Country Application number Is
show all

ANNUAL REPORT 2012 - TiGenix

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?